Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Reports Further Validation of Infectech's Identikit Technology
November 03, 2004

Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that its holding, Infectech, Inc. has received further verification of its technology by Dr. Paul Hyman of Ohio State University. Dr. Hyman has achieved the identification of Mycobacteria Avium Complex (MAC) using DNA amplification in a much shorter time than can be accomplished with current methodology.

"M. avium could be detected significantly sooner than expected for normal culture techniques," stated Paul Hyman, Ph.D. Dr. Hyman is the primary investigator in Infectech's ongoing validation studies. "Sufficient DNA for PCR (gene amplification) could be extracted from paraffin that had no visible colonies on it," he continued.

Mycobacterium avium and Mycobacterium intracellulare are very similar bacteria which are usually grouped together. In America, they are usually described as Mycobacterium avium complex, or MAC. They belong to the same family as the organism which causes tuberculosis (Mycobacterium tuberculosis). MAC is the primary bacterial infection associated with "wasting syndrome" of HIV/AIDS patients and is the leading cause of death among these patients worldwide. MAC are routinely resistant to anti-tuberculosis drugs and there has been no standardized method for determining antibiotic sensitivity. In HIV/AIDS patients, MAC is usually diagnosed after symptoms appear. The diagnostic screen utilizes a blood test. At this time, mortality is very high and time to death is estimated at four months.

It has been estimated by world health authorities that more than 70 percent of AIDS patients harbor an MAC infection. The bacteria affect the bone marrow, spleen, liver and lungs. It also compromises the lymph nodes, thereby further destroying the patient's immune system. This may cause high fevers, severe anemia, night sweats, chills, weight loss, loss of appetite and weakness. If the gut is involved, symptoms can include chronic diarrhea with malabsorption of nutrients, and abdominal pain due to ulcers in the gut. It has been shown that MAC also causes opportunistic infections among non-HIV infected pediatric and elderly persons. Infectech's technology allows for the rapid culturing and identification of MAC. It will also provide viable treatment options by testing the particular strain's antibiotic sensitivity. By using saliva or stool samples, this process could identify an infection as much as 10 months before the bacterium could be found in blood samples and well before symptoms begin.

"Dr. Hyman's validation of Infectech's patented technology clearly shows that we can identify a costly disease in a fraction of the time," commented Dr. Mitchell Felder, Chief Executive Officer for Infectech. "These results may also have enormous implications in the treatment of AIDS sufferers, as antibiotic-sensitivity test can now be performed early enough to make a difference in these patients," he added.

Infectech owns 29 issued patents related to the rapid isolation, growth, identification and antibiotic sensitivity of disease-causing bacteria that includes Mycobacterium avium. Infectech's researchers discovered that certain grades of paraffin wax, when used in conjunction with a microscope slide, and combined with a nutrient broth, provides for the rapid isolation, growth and identification of various disease-causing bacteria. Infectech has developed a diagnostic test kit based on this technology. The basic test kit consists of a glass slide coated with paraffin, which is used as a carbon (food) source by certain pathogenic bacterial species such as TB. The slides are incubated in a sample of almost any bodily fluid (a non-invasive sample of saliva is preferred) within a nutrient broth. This creates a semi-solid growth medium for the bacteria, which imitates its natural environment within a human or animal host. The bacteria collect on the paraffin slide in 4-8 days. Testing can then be done to identify the species of bacteria. This testing can be done via acid-fast staining or through PCR gene amplification. Additionally, the bacteria can be cultured with antibiotics to test for specific sensitivities. Through the choice of different nutrient broths, each kit can be tailored to encourage the growth of a specific bacterium. The test kits are being designed to work on a class of bacteria that includes TB, MAC, Para-tuberculosis, Pseudomonas and Nocardia.

"We are very excited about the progress that has been made by Dr. Hyman and Ohio State University," said Rik J Deitsch, Nutra Pharma's Chief Executive Officer. "They have already validated Infectech's Identikit with two very important strains of mycobacterium, MAC and Para-tuberculosis. After some further validation of additional strains, Infectech will seek to gain regulatory approval from the FDA, allowing for the marketing and distribution of the Identikits," he concluded.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The further validation of Infectech's technology should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy


June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics